ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Epygenix Submits IND Application for EPX-100 for Dravet Syndrome americanpharmaceuticalreview
June 26, 2019Epygenix Therapeutics announced the Company has submitted Investigational New Drug Application (IND) and Fast Track Designation Request for EPX-100 to the U.S. Food and Drug Administration (FDA) for the treatment of patients with Dravet syndrome.
Pharma Sources Insight July 2025
